about
Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemiaEffects of applying a standardised management algorithm for moderate to severe renal dysfunction in patients with chronic stable heart failureExpression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney.Data confusion.The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney diseaseMitochondrial dysfunction in uremic cardiomyopathy.The effect of spontaneous twin pregnancy on renal transplant function and haemodynamicsA randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients.Arterio-Venous Fistula: Is it Critical for Prolonged Survival in the over 80's Starting Haemodialysis?Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial.A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia.Beyond efficacy and safety-the need for convenient and cost-effective iron therapy in health careSafety of intravenous iron use in chronic kidney disease.Biomarkers of Tolerance in Kidney Transplantation: Are We Predicting Tolerance or Response to Immunosuppressive Treatment?Analysis of factors predicting mortality of new patients commencing renal replacement therapy 10 years of follow-up.Cellular basis of uraemic cardiomyopathy: a role for erythropoietin?Uremic cardiomyopathy and insulin resistance: a critical role for akt?Risk factors and metabolic mechanisms in the pathogenesis of uraemic cardiac disease.Value of carnitine therapy in kidney dialysis patients and effects on cardiac function from human and animal studies.High glucose enhances store-operated calcium entry by upregulating ORAI/STIM via calcineurin-NFAT signalling.A systematic review of known interventions for the treatment of chronic nonhypovolaemic hypotonic hyponatraemia and a meta-analysis of the vaptans.Renal Squamous Cell Carcinoma of a Native Kidney After Renal Transplant: A Case Report.Iron (III) isomaltoside 1000.Cathasept Line Lock and Microbial Colonization of Tunneled Hemodialysis Catheters: A Multicenter Randomized Controlled Trial.Accessing emergency test results on ward computers. Results indicating that lifesaving treatment is needed should probably be telephoned.Rapidly growing non-tuberculous mycobacterial infection in a renal transplant patient after alemtuzumab induction.Bedside tipple?Man's best friend: life threatening sepsis after minor dog bite.Iatrogenic gall bladder perforation.Fulminant psittacosis.Photopheresis therapy for problematic renal allograft rejection.South Asian hospitals that lack DNAR orders deny patients holistic care.Acute interstitial nephritis induced by glucosamine.Efficacy and tolerability of accelerated-dose low-molecular-weight iron dextran (Cosmofer) in patients with chronic kidney disease.Accelerated total dose infusion of low molecular weight iron dextran is safe and efficacious in chronic kidney disease patients.Barriers to patient participation in a self-management and education website Renal PatientView: A questionnaire-based study of inactive users.Happy, 'healthy' and enjoying life on dialysis: an elderly perspective.Correction of iron deficiency anaemia using IV CosmoFer in CKD patients with asthma: a prospective study.Influences of the N- and C-termini of the distal nephron inward rectifier, ROMK.Steroid regulation: An overlooked aspect of tolerance and chronic rejection in kidney transplantation.
P50
Q26750413-8142F31D-AA3B-41C1-82DE-7236293AD89DQ28212766-7E36E035-03F3-431F-BE4E-2AA32CB3DFDDQ30487782-341D30AE-151F-40D1-9045-D35FB27149C1Q31031112-004D47FC-1F63-4E20-A9C8-37B21ED40503Q34237283-8B2903E1-2171-42A0-A993-E0EF46595E2EQ35178622-3FED7BDD-8297-41D3-9CB1-369B3256993CQ35574316-1BB694B6-AFFB-45BE-9990-208C69E29892Q35998091-E764B9A0-B775-4295-A624-9B38B1556EB0Q36147733-90B55B4A-786E-4E5C-8019-30E1D685C13FQ36497887-2A7DF44D-23ED-4C36-86E1-3383E0CFE933Q36722337-90D6A71B-B728-48BF-89CF-F9D048C1A4E4Q36745330-4C3A0A19-B0F1-42B6-AD78-C1F87C3A57F9Q37320585-1D7FCE94-C766-4194-9701-F8299A5C4C17Q37462039-B1869841-719E-47B2-9A40-7005035DAD79Q37516975-E7ED0E3A-EE06-4C46-9775-11100BBF0724Q37562631-C1FFE230-9617-4FBD-9486-96ED07350CBFQ37773105-6B1DB337-B347-4799-A7A6-2A6DBFBF498BQ37825209-002DD285-6052-45D9-BC1B-AFC0CD332945Q37971938-5FFAB61C-436C-4A97-ADBD-CF8150B51AC8Q38932529-B11F0E60-3119-45BC-A5CC-8B61CAA2B35DQ38954068-C9EC838B-0F17-465E-B592-11A20C27BAE6Q39099674-DDE7F5F3-4399-4044-BD3C-30D5F6FB4981Q39399976-84C14142-6C9E-440E-A892-547031B46891Q41124289-9E8A1C04-0B8C-40FA-B663-99CDB66EB1F4Q42044215-B41DBA8B-92A9-4EDF-8B51-843EDEF56F91Q42205422-66150EF8-2407-440F-B107-C454A683F816Q42506911-677CC14D-E8CD-4D39-901D-DE74B2E97B5CQ42781257-47BFC152-2CE9-40A3-A36A-A38594F57D2CQ43239023-A2177CEB-8259-446A-8F8A-EE7913566281Q43432729-9E790340-E33E-433C-ACCF-1EB611B71477Q45964213-A010C96D-9318-485F-B485-22E14012DF9BQ46070893-2EC3707D-2CA0-44C7-A139-EE306C7CD5BDQ46966219-89AD64D7-249F-485F-807A-B035B2664A4EQ47336715-95DE4C75-2E7D-452F-86E8-30F820D475A3Q47409348-D77071DF-950D-4605-BFAE-4A0D427497D7Q47577145-32379D9D-5EBB-4F09-88EF-4C5E14175A7AQ48160514-55A8178B-2E5F-4532-A62A-FC9BAB202F56Q48787043-5C356615-FA34-4697-8E44-A69396E42DDAQ48880116-3139F173-0362-48D6-8851-CA034717F085Q50087170-E408EDCF-3EDE-4700-BB0E-9ED4C7DF3CC8
P50
description
researcher
@en
researcher
@en-gb
wetenschapper
@nl
հետազոտող
@hy
name
Sunil Bhandari
@ast
Sunil Bhandari
@en
Sunil Bhandari
@en-gb
Sunil Bhandari
@es
Sunil Bhandari
@nl
Sunil Bhandari
@sl
type
label
Sunil Bhandari
@ast
Sunil Bhandari
@en
Sunil Bhandari
@en-gb
Sunil Bhandari
@es
Sunil Bhandari
@nl
Sunil Bhandari
@sl
prefLabel
Sunil Bhandari
@ast
Sunil Bhandari
@en
Sunil Bhandari
@en-gb
Sunil Bhandari
@es
Sunil Bhandari
@nl
Sunil Bhandari
@sl
P106
P1153
7102035384
P31
P496
0000-0002-0996-9622